ABVX — Abivax S.A.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1956827 ·
France
Last close
$125.70
Market Cap
$10.96B
52W High
$147.98
52W Low
$69.81
ADV30
2,011,407
Next earnings
2026-09-21
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -56,229,000 | -48,468,000 | 547,142,000 | 477,423,000 | 117,548,000 |
| Dec 2025 | 0 | — | -71,648,000 | -81,960,000 | 584,341,000 | 516,685,000 | 129,136,000 |
| Sep 2025 | 0 | — | -80,712,000 | -153,358,000 | 652,052,000 | 589,703,000 | 140,814,000 |
| Jun 2025 | 0 | — | -46,496,000 | -48,414,000 | 119,641,000 | 60,946,000 | 167,921,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-161,130,000
Investing CF
$-8,193,000
Financing CF
$547,307,000
CapEx
$-243,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-4.56
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-738,482,000
Inventory
—
Receivables
$10,495,000
ST Investments
$13,698,000
EBIT TTM
$-302,711,000
Pretax Income TTM
$-330,254,000
Interest Exp TTM
$27,543,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,920,000
EBITDA
$-254,004,000
Free Cash Flow
$-114,471,872
Enterprise Value
$9,942,491,136
Total Cash
$491,552,000
Total Debt
$34,211,000
Shares Out
87,160,669
Trailing EPS
$-5.26
Book Value
$6.18
ROE
-157.1%
ROA
-44.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -246,056,000 | -336,102,000 | 584,341,000 | 129,136,000 | — | -161,129,000 |
| Dec 2024 | 0 | -172,984,000 | -176,242,000 | 205,228,000 | 164,644,000 | — | -154,072,000 |
| Dec 2023 | 0 | -127,377,000 | -147,740,000 | 327,062,000 | 131,052,000 | — | -97,130,000 |
| Dec 2022 | 0 | -51,205,000 | -60,740,000 | 75,544,000 | 68,355,000 | — | -53,936,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.15
Max Pain — expiry 2026-07-31
max pain strike: $125.00 · spot: $125.70 · call oi: 4,262 · put oi: 2,765
Expected Move to 2026-07-31:
±$9.50
(7.56%) —
implied range
$116.20 –
$135.20
· ATM straddle on $126.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CYTK | CYTOKINETICS INC | $10.96B | $80.74 | — |
| SMMT | Summit Therapeutics Inc. | $10.60B | $13.66 | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.47B | $59.33 | — |
| CORT | CORCEPT THERAPEUTICS INC | $10.24B | $95.36 | — |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $12.06B | $85.60 | — |
News headlines (Yahoo Finance, 1h cache)
Abivax (ENXTPA:ABVX) Adds Commercial Leaders And Signs Valerio R And D Deal
2026-07-25 10:07 · Yahoo
Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
2026-07-23 20:05 · Yahoo
Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update
2026-07-16 07:07 · Yahoo
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?
2026-07-10 13:55 · Yahoo
Abivax CEO says $920M raise funds U.S. drug launch without Big Pharma
2026-07-10 13:35 · Yahoo
3 Soaring Stocks That May Have More Upside Ahead
2026-07-07 23:35 · Yahoo
Abivax: Wall Street Catches Up to the Data
2026-07-07 16:25 · Yahoo
Abivax Announces Closing of $920 Million Public Offering
2026-07-06 20:05 · Yahoo
Abivax Rebounds, but Obefazimod Unlikely to Replace JAK Inhibitors, Wedbush Says
2026-07-06 15:12 · Yahoo
Is ABIVAX Société Anonyme (ABVX) A Good Stock To Buy Now?
2026-07-03 23:32 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.